AstraZenecom Dagrid China was approved

On February 4, AstraZeneca announced that Andaltang ® (common name: Dagley Net) has been officially approved in China for the treatment of patients with reduced blood test scores in adults (HFrEF, NYHA II-IV), reducing the risk of cardiovascular death and hospitalization for heart failure (hHF).
chronic heart failure is a fatal disease that can lead to a decline in heart pump blood function and is difficult to meet the body's needs.
At least half of these patients have reduced blood fractional heart failure (HFrEF), which usually manifests it as a failure of the left cercardial heart muscle to contract sufficiently, resulting in a reduction in the blood supply to circulatory and exoskeletosis.
daglie's approval in China is based on positive results from the landmark DAPA-HF III clinical trial published in the New England Journal of Medicine.
May 2020, china's State Drug Administration (NMPA) Drug Review Center (CDE) included DAPA-HF research in its priority review.
About heart failure (HF) affects about 64 million people worldwide (at least half of whom are shot fractional-reduced heart failure), including 15 million in the European Union, 6 million in the United States and 7 million treated adult heart failure patients in China.
heart failure is a chronic disease, with more than half of patients dying within five years of diagnosis.
The heart failure is divided into two broad categories based on the value of the shot fraction (EF: i.e., the percentage of the volume of the end-stage volume of the chamber throbbing) per beat output): the shot fraction reduction heart failure (HFrEF) and the shot fraction retention heart failure (HFpEF).
, the reduced blood score is manifested in the failure of the left cercardial heart muscle to contract sufficiently, resulting in a reduction in the blood supply of circulatory and exoskeletosis tissue.
Heart failure is as deadly as some of the most common cancers in men (prostate and bladder) and women (breast cancer) and is a major cause of hospitalization for patients over 65 years of age, facing a significant clinical burden on doctors and a huge financial burden on patients.
: The original text has a deletion of reference 1. Mayo Clinic. Heart Failure; 29 May 2020 [cited 5 January 2021]. Available from:URL: Travessa AMR, Menezes Falcão LF de. Treatment of Heart Failure With Reduced Ejection Fraction-Recent Developments. Am J Ther 2016; 23(2):e531-49.3. American Heart Association. Ejection Fraction Heart Failure Measurement; 2017 [cited 2 Nov 2020]. Available from: URL: Ponikowski P et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27):2129–200.5. National Guideline Centre (UK). Chronic Heart Failure in Adults: Diagnosis and Management. London: National Institute for Health and Care Excellence (UK); 2018 Sep. (NICE Guideline, No. 106.) 13, Glossary.6. McMurray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381(21):1995–2008.7. Vos T et al. Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 328 Diseases and Injuries for 195 Countries, 1990–2016: A Systematic Analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390(10100):1211–59.8. Dickstein K et al. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in Collaboration with the Heart Failure Association of the ESC (HFA) and Endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388–442.9. Centers for Disease Control and Prevention. Heart Disease: Heart Failure. 8 September 2020. #:~:text=Facts%20About%20Heart%20Failure%20in,estimated%20%2430.7%20billion%20in%202012.10. AstraZeneca. Data on File. February 2020.11. Mozaffarian D et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 2016; 133(4):e38–360.12. Mamas MA et al. Do Patients Have Worse Outcomes in Heart Failure than in Cancer? A Primary Care-Based Cohort Study with 10-year Follow-up in Scotland. Eur J Heart Fail 2017; 19(9):1095–104.13. Azad N, Lemay G. Management of Chronic Heart Failure in the Older Population. J Geriatr Cardiol 2014; 11(4):329–37.